Switzerland: Johnson & Johnson to obtain rights to develop Numab’s NM26 for US$1.25bn

Numab Therapeutics, a clinical stage biotechnology company, is selling Yellow Jersey Therapeutics (YJT), a wholly-owned subsidiary of Numab, to US-based multinational Johnson & Johnson for US$1.25bn. YJT, to be spun-off […]